SUPPLEMENT

Q4 2023 — Financial disclosures

Q4 2023PDF · 10 pages1.1 MB
Merck & Co., Inc.
Financial Highlights Package
Fourth Quarter 2023
Table of Contents
Table 1: GAAP P&L.....................................................................................1
Table 1a: GAAP P&L – Current Year and Prior Year by Quarter..................2
Table 2a: GAAP to Non-GAAP Reconciliation 4Q23 and Dec YTD 23.........3
Table 2b: GAAP to Non-GAAP Reconciliation 4Q22 and Dec YTD 22.. ......4
Table 3: Sales - Current Year and Prior Year by Quarter...........................5
Table 3a: Sales – U.S. / Ex- U.S. 4Q23........................................................6
Table 3b: Sales – U.S. / Ex- U.S. Dec YTD 23..............................................7
Table 3c: Sales – Pharmaceutical Geographic Split.....................................8
Table 4: Other (Income) Expense ..............................................................9

-- 1 of 10 --

Sales 	14,630	$ 	13,830	$ 	6% 	60,115	$ 	59,283	$ 	1%
Costs, Expenses and Other
Cost of sales 	3,911 	3,881 	1% 	16,126 	17,411 	-7%
Selling, general and administrative 	2,804 	2,687 	4% 	10,504 	10,042 	5%
Research and development 	9,628 	3,775 	* 	30,531 	13,548 	*
Restructuring costs 	255 	49 	* 	599 	337 	78%
Other (income) expense, net 	78 	(75) 	* 	466 	1,501 	-69%
(Loss) Income Before Taxes 	(2,046) 	3,513 	* 	1,889 	16,444 	-89%
Income Tax (Benefit) Provision 	(821) 	495 	1,512 	1,918
Net (Loss) Income 	(1,225) 	3,018 	* 	377 	14,526 	-97%
Less: Net Income Attributable to Noncontrolling Interests 	1 	1 	12 	7
Net (Loss) Income Attributable to Merck & Co., Inc. 	(1,226)	$ 	3,017	$ 	* 	365	$ 	14,519	$ 	-97%
(Loss) Earnings per Common Share Assuming Dilution (1) 	(0.48)	$ 	1.18	$ 	* 	0.14	$ 	5.71	$ 	-98%
Average Shares Outstanding Assuming Dilution (1) 	2,533 	2,548 	2,547 	2,542
Tax Rate 	40.1% 	14.1% 	80.0% 	11.7%
* 100% or greater
(1) Because the company recorded a net loss in the fourth quarter of 2023, no potential dilutive common shares were used in the computation of loss per common share assuming
dilution as the effect would have been anti-dilutive.
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1
GAAP
% Change
GAAP
% Change
4Q23 	4Q22 Full Year
2023
Full Year
2022
1

-- 2 of 10 --

Sales 	14,487	$ 	15,035	$ 	15,962	$ 	14,630	$ 	60,115	$ 	15,901	$ 	14,593	$ 	14,959	$ 	13,830	$ 	59,283	$ 	6% 	1%
Costs, Expenses and Other
Cost of sales 	3,926 	4,024 	4,264 	3,911 	16,126 	5,380 	4,216 	3,934 	3,881 	17,411 	1% 	-7%
Selling, general and administrative 	2,479 	2,702 	2,519 	2,804 	10,504 	2,323 	2,512 	2,520 	2,687 	10,042 	4% 	5%
Research and development 	4,276 	13,321 	3,307 	9,628 	30,531 	2,576 	2,798 	4,399 	3,775 	13,548 	* 	*
Restructuring costs 	67 	151 	126 	255 	599 	53 	142 	94 	49 	337 	* 	78%
Other (income) expense, net 	89 	172 	126 	78 	466 	708 	438 	429 	(75) 	1,501 	* 	-69%
Income (Loss) Before Taxes 	3,650 	(5,335) 	5,620 	(2,046) 	1,889 	4,861 	4,487 	3,583 	3,513 	16,444 	* 	-89%
Income Tax Provision (Benefit) 	825 	637 	870 	(821) 	1,512 	554 	538 	330 	495 	1,918
Net Income (Loss) 	2,825 	(5,972) 	4,750 	(1,225) 	377 	4,307 	3,949 	3,253 	3,018 	14,526 	* 	-97%
Less: Net Income (Loss) Attributable to Noncontrolling Interests 	4 	3 	5 	1 	12 	(3) 	5 	5 	1 	7
Net Income (Loss) Attributable to Merck & Co., Inc. 	2,821	$ 	(5,975)	$ 	4,745	$ 	(1,226)	$ 	365	$ 	4,310	$ 	3,944	$ 	3,248	$ 	3,017	$ 	14,519	$ 	* 	-97%
Earnings (Loss) per Common Share Assuming Dilution (1) 	1.11	$ 	(2.35)	$ 	1.86	$ 	(0.48)	$ 	0.14	$ 	1.70	$ 	1.55	$ 	1.28	$ 	1.18	$ 	5.71	$ 	* 	-98%
Average Shares Outstanding Assuming Dilution (1) 	2,551 	2,539 	2,546 	2,533 	2,547 	2,537 	2,540 	2,542 	2,548 	2,542
Tax Rate 	22.6% 	-11.9% 	15.5% 	40.1% 	80.0% 	11.4% 	12.0% 	9.2% 	14.1% 	11.7%
* 100% or greater
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
% Change
4Q 	Full
Year
(1) Because the company recorded a net loss in the second and fourth quarters of 2023, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect
would have been anti-dilutive.
2023
2Q 	3Q 	4Q 	Full Year	1Q 	1Q 	2Q 	3Q 	4Q 	Full Year
2022
Table 1a
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
2

-- 3 of 10 --

Fourth Quarter
Cost of sales 	3,911	$ 	454 	117 	571 	3,340	$
Selling, general and administrative 	2,804 	24 	29 	53 	2,751
Research and development 	9,628 	790 	790 	8,838
Restructuring costs 	255 	255 	255 	–
Other (income) expense, net 	78 	(35) 	(61) 	(96) 	174
Loss Before Taxes 	(2,046) 	(1,233) 	(401) 	61 	(1,573) 	(473)
Income Tax Provision (Benefit) 	(821) 	(227) (4) 	(67) (4) 	13 (4) 	(281) 	(540)
Net (Loss) Income 	(1,225) 	(1,006) 	(334) 	48 	(1,292) 	67
Net (Loss) Income Attributable to Merck & Co., Inc. 	(1,226) 	(1,006) 	(334) 	48 	(1,292) 	66
(Loss) Earnings per Common Share Assuming Dilution (5) 	(0.48)	$ 	(0.40) 	(0.13) 	0.02 	(0.51) 	0.03	$
Tax Rate 	40.1% 	114.2%
Full Year
Cost of sales 	16,126	$ 	2,018 	211 	2,229 	13,897	$
Selling, general and administrative 	10,504 	86 	122 	208 	10,296
Research and development 	30,531 	819 	1 	820 	29,711
Restructuring costs 	599 	599 	599 	–
Other (income) expense, net 	466 	(47) 	(279) 	573 (3) 	247 	219
Income Before Taxes 	1,889 	(2,876) 	(933) 	279 	(573) 	(4,103) 	5,992
Income Tax Provision (Benefit) 	1,512 	(476) (4) 	(155) (4) 	60 (4) 	(60) (4) 	(631) 	2,143
Net Income 	377 	(2,400) 	(778) 	219 	(513) 	(3,472) 	3,849
Net Income Attributable to Merck & Co., Inc. 	365 	(2,400) 	(778) 	219 	(513) 	(3,472) 	3,837
Earnings per Common Share Assuming Dilution 	0.14	$ 	(0.94) 	(0.31) 	0.08 	(0.20) 	(1.37) 	1.51	$
Tax Rate 	80.0% 	35.8%
Only the line items that are affected by non-GAAP adjustments are shown.
MERCK & CO., INC.
FOURTH QUARTER AND FULL YEAR 2023 GAAP TO NON-GAAP RECONCILIATION
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2a
(4) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
(5) Because the company recorded a net loss in the fourth quarter of 2023, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive.
Adjustment Subtotal 	Non-GAAP
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-
GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and
to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in
addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and
divestitures. Amounts included in research and development expenses primarily reflect a $779 million in-process research and development (IPR&D) impairment charge related to gefapixant, which was obtained as part of the 2016 Afferent
Pharmaceuticals acquisition, and expenses for the amortization of intangible assets. Amounts included in other (income) expense, net, primarily reflect royalty income related to the prior termination of the Sanofi-Pasteur MSD joint venture.
Additionally, other (income) expense, net, for the full year includes a $37 million loss on the sale of a business.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.
(3) Reflects a charge related to settlements with certain plaintiffs in the Zetia antitrust litigation.
GAAP 	Acquisition and Divestiture-
Related Costs (1) 	Restructuring Costs (2)	
(Income) Loss from
Investments in Equity
Securities
Certain Other Items
3

-- 4 of 10 --

Fourth Quarter
Cost of sales 	3,881	$ 	482 	38 	520 	3,361	$
Selling, general and administrative 	2,687 	39 	20 	59 	2,628
Research and development 	3,775 	740 	740 	3,035
Restructuring costs 	49 	49 	49 	–
Other (income) expense, net 	(75) 	(69) 	80 	11 	(86)
Income Before Taxes 	3,513 	(1,192) 	(107) 	(80) 	(1,379) 	4,892
Income Tax Provision (Benefit) 	495 	(222) (3) 	(32) (3) 	(13) (3) 	(267) 	762
Net Income 	3,018 	(970) 	(75) 	(67) 	(1,112) 	4,130
Net Income Attributable to Merck & Co., Inc. 	3,017 	(970) 	(75) 	(67) 	(1,112) 	4,129
Earnings per Common Share Assuming Dilution 	1.18	$ 	(0.38) 	(0.03) 	(0.03) 	(0.44) 	1.62	$
Tax Rate 	14.1% 	15.6%
Full Year
Cost of sales 	17,411	$ 	2,059 	205 	2,264 	15,147	$
Selling, general and administrative 	10,042 	176 	94 	270 	9,772
Research and development 	13,548 	1,676 	30 	1,706 	11,842
Restructuring costs 	337 	337 	337 	–
Other (income) expense, net 	1,501 	(207) 	1,348 	1,141 	360
Income Before Taxes 	16,444 	(3,704) 	(666) 	(1,348) 	(5,718) 	22,162
Income Tax Provision (Benefit) 	1,918 	(809) (3) 	(129) (3) 	(294) (3) 	(1,232) 	3,150
Net Income 	14,526 	(2,895) 	(537) 	(1,054) 	(4,486) 	19,012
Net Income Attributable to Merck & Co., Inc. 	14,519 	(2,895) 	(537) 	(1,054) 	(4,486) 	19,005
Earnings per Common Share Assuming Dilution 	5.71	$ 	(1.14) 	(0.21) 	(0.42) 	(1.77) 	7.48	$
Tax Rate 	11.7% 	14.2%
Only the line items that are affected by non-GAAP adjustments are shown.
MERCK & CO., INC.
FOURTH QUARTER AND FULL YEAR 2022 GAAP TO NON-GAAP RECONCILIATION
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2b
Non-GAAP
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends.
Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management
uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is
derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with
GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain
other costs related to acquisitions and divestitures. Amounts included in research and development expenses for the fourth quarter and full year primarily reflect $780 million and $1.7 billion, respectively, of
intangible asset impairment charges largely related to nemtabrutinib, which was obtained as part of the 2020 ArQule, Inc. acquisition, and expenses for the amortization of intangible assets, partially offset by a
reduction in expenses related to changes in the estimated fair value of liabilities for contingent consideration. Amounts included in other (income) expense, net, reflect royalty income and decreases in the
estimated fair value measurement of liabilities for contingent consideration related to the prior termination of the Sanofi-Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.
(3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
GAAP 	Acquisition and Divestiture-
Related Costs (1) 	Restructuring Costs (2)	
(Income) Loss from
Investments in Equity
Securities
Adjustment Subtotal
4

-- 5 of 10 --

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3
2023 	2022 	4Q 	Full Year
1Q 	2Q 	3Q 	4Q 	Full Year 	1Q 	2Q 	3Q 	4Q 	Full Year 	Nom % Ex-Exch % 	Nom % Ex-Exch %
TOTAL SALES (1) 	$14,487 	$15,035 	$15,962 	$14,630 	$60,115 	$15,901 	$14,593 	$14,959 	$13,830 	$59,283 	6 	7 	1 	4
PHARMACEUTICAL 	12,721 	13,457 	14,263 	13,141 	53,583 	14,107 	12,756 	12,963 	12,180 	52,005 	8 	8 	3 	5
Oncology
Keytruda 	5,795 	6,271 	6,338 	6,608 	25,011 	4,809 	5,252 	5,426 	5,450 	20,937 	21 	22 	19 	21
Alliance Revenue – Lynparza (2) 	275 	310 	299 	315 	1,199 	266 	275 	284 	292 	1,116 	8 	8 	7 	9
Alliance Revenue – Lenvima (2) 	232 	242 	260 	226 	960 	227 	231 	202 	216 	876 	5 	5 	10 	11
Welireg 	42 	50 	54 	72 	218 	18 	27 	38 	40 	123 	79 	78 	77 	77
Alliance Revenue – Reblozyl (3) 	43 	47 	52 	70 	212 	52 	33 	39 	41 	166 	69 	69 	28 	28
Vaccines (4)
Gardasil / Gardasil 9 	1,972 	2,458 	2,585 	1,871 	8,886 	1,460 	1,674 	2,294 	1,470 	6,897 	27 	27 	29 	33
ProQuad / M-M-R II / Varivax 	528 	582 	713 	545 	2,368 	470 	578 	668 	526 	2,241 	4 	3 	6 	6
RotaTeq 	297 	131 	156 	185 	769 	216 	173 	256 	139 	783 	34 	33 	-2 	-1
Vaxneuvance 	106 	168 	214 	176 	665 	5 	12 	16 	138 	170 	28 	26 	* 	*
Pneumovax 23 	96 	92 	140 	85 	412 	173 	153 	131 	145 	602 	-42 	-43 	-32 	-31
Vaqta 	40 	42 	69 	29 	180 	36 	35 	64 	39 	173 	-24 	-25 	4 	4
Hospital Acute Care
Bridion 	487 	502 	424 	429 	1,842 	395 	426 	423 	441 	1,685 	-3 	-3 	9 	11
Prevymis 	129 	143 	157 	175 	605 	94 	103 	114 	118 	428 	49 	49 	41 	43
Dificid 	65 	76 	74 	87 	302 	52 	66 	77 	67 	263 	30 	30 	15 	15
Zerbaxa 	50 	54 	53 	61 	218 	30 	46 	43 	49 	169 	25 	23 	29 	30
Noxafil 	60 	55 	51 	46 	213 	57 	60 	62 	58 	238 	-21 	-16 	-11 	-4
Primaxin 	80 	53 	41 	39 	213 	58 	64 	63 	54 	239 	-28 	-28 	-11 	-6
Cardiovascular
Alliance Revenue - Adempas/Verquvo (5) 	99 	68 	92 	108 	367 	72 	98 	88 	82 	341 	31 	31 	8 	8
Adempas (6) 	59 	65 	65 	66 	255 	61 	63 	57 	57 	238 	15 	11 	7 	8
Virology
Lagevrio 	392 	203 	640 	193 	1,428 	3,247 	1,177 	436 	825 	5,684 	-77 	-76 	-75 	-74
Isentress / Isentress HD 	123 	136 	119 	105 	483 	158 	147 	161 	167 	633 	-37 	-37 	-24 	-23
Neuroscience
Belsomra 	56 	63 	58 	54 	231 	69 	69 	62 	59 	258 	-8 	-6 	-11 	-6
Immunology
Simponi 	180 	180 	179 	171 	710 	186 	181 	173 	166 	706 	3 	-2 	1 	-
Remicade 	51 	48 	45 	43 	187 	61 	53 	49 	44 	207 	-1 	-2 	-9 	-8
Diabetes (7)
Januvia 	551 	511 	581 	547 	2,189 	779 	756 	717 	561 	2,813 	-2 	-2 	-22 	-20
Janumet 	329 	354 	255 	240 	1,177 	454 	476 	417 	353 	1,700 	-32 	-32 	-31 	-29
Other Pharmaceutical (8) 	584 	553 	549 	595 	2,283 	602 	528 	603 	583 	2,319 	2 	2 	-2 	-
ANIMAL HEALTH 	1,491 	1,456 	1,400 	1,278 	5,625 	1,482 	1,467 	1,371 	1,230 	5,550 	4 	4 	1 	3
Livestock 	849 	807 	874 	808 	3,337 	832 	826 	829 	814 	3,300 	-1 	- 	1 	4
Companion Animal 	642 	649 	526 	470 	2,288 	650 	641 	542 	416 	2,250 	13 	12 	2 	3
Other Revenues (9) 	275 	122 	299 	211 	907 	312 	370 	625 	420 	1,728 	-50 	-1 	-48 	-15
*200% or greater
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(7) Total Diabetes sales were $950 million, $951 million, $924 million and $876 million in the first, second, third and fourth quarter of 2023, respectively, and $1,305 million, $1,300 million, $1,231 million
and $1,012 million in the first, second, third and fourth quarter of 2022, respectively.
(8) Includes Pharmaceutical products not individually shown above.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues
related to the receipt of upfront and milestone payments for out-licensed products were $51 million, $3 million and $65 million in the first, second and third quarter of 2023, respectively, and $114 million,
$32 million, $10 million and $10 million in the first, second, third and fourth quarter of 2022, respectively.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties and a milestone payment of $20 million received in the first quarter of 2022.
(4) Total Vaccines sales were $3,133 million, $3,557 million, $4,002 million and $2,962 million in the first, second, third and fourth quarter of 2023, respectively, and $2,481 million, $2,709 million, $3,552
million and $2,554 million in the first, second, third and fourth quarter of 2022, respectively.
(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(6) Net product sales in Merck's marketing territories.
5

-- 6 of 10 --

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
FOURTH QUARTER 2023
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3a
Global 	U.S. 	International
4Q 2023 	4Q 2022 	% Change 	4Q 2023 	4Q 2022 	% Change 	4Q 2023 	4Q 2022 	% Change
TOTAL SALES (1) 	$14,630 	$13,830 	6 	$7,088 	$6,279 	13 	$7,542 	$7,551 	-
PHARMACEUTICAL 	13,141 	12,180 	8 	6,698 	5,871 	14 	6,443 	6,309 	2
Oncology
Keytruda 	6,608 	5,450 	21 	3,972 	3,378 	18 	2,636 	2,071 	27
Alliance Revenue – Lynparza (2) 	315 	292 	8 	168 	157 	7 	147 	135 	9
Alliance Revenue – Lenvima (2) 	226 	216 	5 	181 	154 	18 	45 	62 	-28
Welireg 	72 	40 	79 	68 	40 	70 	4 	-
Alliance Revenue – Reblozyl (3) 	70 	41 	69 	60 	36 	68 	10 	6 	74
Vaccines (4)
Gardasil / Gardasil 9 	1,871 	1,470 	27 	365 	262 	39 	1,506 	1,207 	25
ProQuad / M-M-R II / Varivax 	545 	526 	4 	402 	387 	4 	143 	139 	3
RotaTeq 	185 	139 	34 	112 	82 	37 	73 	57 	28
Vaxneuvance 	176 	138 	28 	138 	132 	5 	38 	6 	*
Pneumovax 23 	85 	145 	-42 	22 	66 	-66 	62 	79 	-21
Vaqta 	29 	39 	-24 	28 	23 	24 	1 	16 	-94
Hospital Acute Care
Bridion 	429 	441 	-3 	315 	257 	22 	113 	183 	-38
Prevymis 	175 	118 	49 	78 	52 	49 	98 	65 	50
Dificid 	87 	67 	30 	75 	57 	32 	12 	10 	17
Zerbaxa 	61 	49 	25 	33 	25 	31 	28 	24 	18
Noxafil 	46 	58 	-21 	4 	13 	-72 	43 	46 	-7
Primaxin 	39 	54 	-28 	1 	N/M 	39 	53 	-27
Cardiovascular
Alliance Revenue - Adempas/Verquvo (5) 	108 	82 	31 	102 	85 	20 	6 	-2 	*
Adempas (6) 	66 	57 	15 	66 	57 	15
Virology
Lagevrio 	193 	825 	-77 	10 	- 	183 	825 	-78
Isentress / Isentress HD 	105 	167 	-37 	50 	78 	-36 	56 	89 	-38
Neuroscience
Belsomra 	54 	59 	-8 	21 	19 	10 	33 	39 	-17
Immunology
Simponi 	171 	166 	3 	171 	166 	3
Remicade 	43 	44 	-1 	43 	44 	-1
Diabetes (7)
Januvia 	547 	561 	-2 	309 	290 	6 	239 	271 	-12
Janumet 	240 	353 	-32 	41 	97 	-58 	198 	255 	-22
Other Pharmaceutical (8) 	595 	583 	2 	144 	180 	-20 	450 	406 	11
ANIMAL HEALTH 	1,278 	1,230 	4 	387 	396 	-2 	891 	834 	7
Livestock 	808 	814 	-1 	158 	188 	-16 	649 	626 	4
Companion Animal 	470 	416 	13 	229 	208 	10 	242 	208 	16
Other Revenues (9) 	211 	420 	-50 	3 	12 	-75 	208 	408 	-49
*200% or greater
N/M - Not Meaningful
(6) Net product sales in Merck's marketing territories.
(7) Total Diabetes sales were $876 million in the fourth quarter of 2023 and $1,012 million in the fourth quarter of 2022.
(8) Includes Pharmaceutical products not individually shown above.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues,
including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were
$10 million in the fourth quarter of 2022.
Sum of U.S. plus international may not equal global due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.
(4) Total Vaccines sales were $2,962 million in the fourth quarter of 2023 and $2,554 million in the fourth quarter of 2022.
(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and
commercialization costs.
6

-- 7 of 10 --

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
FULL YEAR 2023
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3b
Global 	U.S. 	International
Full Year
2023
Full Year
2022 	% Change 	Full Year 2023
Full Year
2022 	% Change
Full Year
2023
Full Year
2022 	% Change
TOTAL SALES (1) 	$60,115 	$59,283 	1 	$28,480 	$27,206 	5 	$31,635 	$32,077 	-1
PHARMACEUTICAL 	53,583 	52,005 	3 	26,539 	24,989 	6 	27,044 	27,016 	-
Oncology
Keytruda 	25,011 	20,937 	19 	15,114 	12,686 	19 	9,897 	8,251 	20
Alliance Revenue – Lynparza (2) 	1,199 	1,116 	7 	607 	584 	4 	592 	532 	11
Alliance Revenue – Lenvima (2) 	960 	876 	10 	657 	579 	13 	303 	297 	2
Welireg 	218 	123 	77 	209 	123 	70 	10 	-
Alliance Revenue – Reblozyl (3) 	212 	166 	28 	168 	123 	37 	43 	43 	1
Vaccines (4)
Gardasil / Gardasil 9 	8,886 	6,897 	29 	2,083 	2,065 	1 	6,803 	4,832 	41
ProQuad / M-M-R II / Varivax 	2,368 	2,241 	6 	1,837 	1,724 	7 	531 	518 	3
RotaTeq 	769 	783 	-2 	493 	508 	-3 	276 	275 	-
Vaxneuvance 	665 	170 	* 	561 	163 	* 	103 	7 	*
Pneumovax 23 	412 	602 	-32 	127 	346 	-63 	285 	256 	11
Vaqta 	180 	173 	4 	119 	95 	25 	61 	78 	-21
Hospital Acute Care
Bridion 	1,842 	1,685 	9 	1,156 	922 	25 	686 	762 	-10
Prevymis 	605 	428 	41 	264 	188 	40 	341 	240 	42
Dificid 	302 	263 	15 	274 	241 	14 	28 	22 	25
Zerbaxa 	218 	169 	29 	119 	89 	33 	100 	79 	25
Noxafil 	213 	238 	-11 	32 	51 	-37 	181 	187 	-3
Primaxin 	213 	239 	-11 	1 	1 	-6 	211 	238 	-11
Cardiovascular
Alliance Revenue - Adempas/Verquvo (5) 	367 	341 	8 	350 	329 	6 	16 	12 	41
Adempas (6) 	255 	238 	7 	255 	238 	7
Virology
Lagevrio 	1,428 	5,684 	-75 	10 	1,523 	-99 	1,418 	4,161 	-66
Isentress / Isentress HD 	483 	633 	-24 	215 	274 	-21 	268 	359 	-25
Neuroscience
Belsomra 	231 	258 	-11 	81 	79 	3 	150 	179 	-16
Immunology
Simponi 	710 	706 	1 	710 	706 	1
Remicade 	187 	207 	-9 	187 	207 	-9
Diabetes (7)
Januvia 	2,189 	2,813 	-22 	1,151 	1,248 	-8 	1,039 	1,565 	-34
Janumet 	1,177 	1,700 	-31 	223 	355 	-37 	954 	1,344 	-29
Other Pharmaceutical (8) 	2,283 	2,319 	-2 	688 	693 	-1 	1,596 	1,628 	-2
ANIMAL HEALTH 	5,625 	5,550 	1 	1,804 	1,822 	-1 	3,821 	3,728 	2
Livestock 	3,337 	3,300 	1 	700 	710 	-1 	2,637 	2,590 	2
Companion Animal 	2,288 	2,250 	2 	1,104 	1,112 	-1 	1,184 	1,138 	4
Other Revenues (9) 	907 	1,728 	-48 	137 	395 	-65 	770 	1,333 	-42
*200% or greater
(6) Net product sales in Merck's marketing territories.
(7) Total Diabetes sales were $3,701 million and $4,848 million on a global basis for December YTD 2023 and 2022, respectively.
(8) Includes Pharmaceutical products not individually shown above.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues,
including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were
$118 million and $165 million on a global basis for December YTD 2023 and 2022, respectively.
Sum of U.S. plus international may not equal global due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties and a milestone payment of $20 million received in the first quarter of 2022.
(4) Total Vaccines sales were $13,654 million and $11,297 million on a global basis for December YTD 2023 and 2022, respectively.
(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and
commercialization costs.
7

-- 8 of 10 --

MERCK & CO., INC.
PHARMACEUTICAL GEOGRAPHIC SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3c
2023 	2022 	% Change
1Q 	2Q 	3Q 	4Q 	Full Year 	1Q 	2Q 	3Q 	4Q 	Full Year 	4Q 	Full Year
TOTAL PHARMACEUTICAL 	$12,721 	$13,457 	$14,263 	$13,141 	$53,583 	$14,107 	$12,756 	$12,963 	$12,180 	$52,005 	8 	3
United States 	6,117 	6,570 	7,153 	6,698 	26,539 	6,773 	5,726 	6,620 	5,871 	24,989 	14 	6
% Pharmaceutical Sales 	48.1% 	48.8% 	50.1% 	51.0% 	49.5% 	48.0% 	44.9% 	51.1% 	48.2% 	48.1%
Europe (1) 	2,326 	2,401 	2,497 	2,491 	9,715 	3,309 	2,677 	2,427 	2,494 	10,906 	- 	-11
% Pharmaceutical Sales 	18.3% 	17.8% 	17.5% 	19.0% 	18.1% 	23.5% 	21.0% 	18.7% 	20.5% 	21.0%
China 	1,694 	1,887 	1,674 	1,456 	6,710 	1,113 	1,355 	1,419 	1,216 	5,102 	20 	32
% Pharmaceutical Sales 	13.3% 	14.0% 	11.7% 	11.1% 	12.5% 	7.9% 	10.6% 	10.9% 	10.0% 	9.8%
Japan 	737 	652 	1,062 	629 	3,081 	965 	1,092 	653 	832 	3,542 	-24 	-13
% Pharmaceutical Sales 	5.8% 	4.8% 	7.4% 	4.8% 	5.7% 	6.8% 	8.6% 	5.0% 	6.8% 	6.8%
Asia Pacific (other than China and Japan) 	703 	705 	636 	616 	2,661 	786 	854 	702 	691 	3,034 	-11 	-12
% Pharmaceutical Sales 	5.5% 	5.2% 	4.5% 	4.7% 	5.0% 	5.6% 	6.7% 	5.4% 	5.7% 	5.8%
Latin America 	470 	566 	696 	596 	2,328 	435 	453 	511 	472 	1,871 	26 	24
% Pharmaceutical Sales 	3.7% 	4.2% 	4.9% 	4.5% 	4.3% 	3.1% 	3.6% 	3.9% 	3.9% 	3.6%
Eastern Europe/Middle East/Africa 	381 	370 	301 	299 	1,351 	450 	339 	360 	320 	1,469 	-7 	-8
% Pharmaceutical Sales 	3.0% 	2.7% 	2.1% 	2.3% 	2.5% 	3.2% 	2.7% 	2.8% 	2.6% 	2.8%
Canada 	141 	127 	133 	138 	540 	189 	166 	166 	158 	678 	-12 	-20
% Pharmaceutical Sales 	1.1% 	0.9% 	0.9% 	1.1% 	1.0% 	1.3% 	1.3% 	1.3% 	1.3% 	1.3%
Other 	152 	179 	111 	218 	658 	87 	94 	105 	126 	414 	73 	59
% Pharmaceutical Sales 	1.2% 	1.6% 	0.9% 	1.5% 	1.4% 	0.6% 	0.6% 	0.9% 	1.0% 	0.8%
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom.
8

-- 9 of 10 --

OTHER (INCOME) EXPENSE, NET
4Q23 	4Q22
Full Year
2023
Full Year
2022
Interest income 	(70)	$ 	(95)	$ 	(365)	$ 	(157)	$
Interest expense 	310 	235 	1,146 	962
Exchange losses 	162 	17 	370 	237
(Income) loss from investments in equity securities, net (1) 	(99) 	59 	(340) 	1,419
Net periodic defined benefit plan (credit) cost other than service cost 	(134) 	(71) 	(498) 	(279)
Other, net 	(91) 	(220) 	153 	(681)
Total 	78	$ 	(75)	$ 	466	$ 	1,501	$
(1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.
Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests
in investment funds are accounted for on a one quarter lag.
MERCK & CO., INC.
OTHER (INCOME) EXPENSE, NET - GAAP
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 4
9

-- 10 of 10 --